End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma

Lale Kostakoglu; Grzegorz S Nowakowski

doi:10.1016/j.cpet.2019.03.001

End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma

Lale Kostakoglu, Grzegorz S Nowakowski

Hematology

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

“PET imaging with fluorodeoxyglucose (FDG), integrated with PET/computed tomography (FDG-PET/CT), is an effective management tool of diffuse large B-cell lymphoma (DLBCL). The results of end-of-treatment (EOT) FDG-PET/CT are more accurate for detection of active disease with residual masses on CT. Complete response defined by EOT FDG-PET/CT (PET-CR) correlates with long-term outcome of patients. Treatment efficacy is determined using EOT PET/CT rather than progression-free survival (PFS) for clinical trials assessing novel drugs. If the correlation of EOT PET/CT with PFS is further proven in large studies and meta-analyses, EOT PET-CR could serve as an expedited novel endpoint replacing PFS.”

Original language	English (US)
Pages (from-to)	307-315
Number of pages	9
Journal	PET Clinics
Volume	14
Issue number	3
DOIs	https://doi.org/10.1016/j.cpet.2019.03.001
State	Published - Jul 1 2019

Keywords

Diffuse large B-cell lymphoma
End-of-treatment PET-CT
FDG-PET/CT
Prediction of outcome

ASJC Scopus subject areas

Radiation
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.cpet.2019.03.001

Cite this

@article{02594d4004b84990802fa0a999d34c71,

title = "End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma",

abstract = "“PET imaging with fluorodeoxyglucose (FDG), integrated with PET/computed tomography (FDG-PET/CT), is an effective management tool of diffuse large B-cell lymphoma (DLBCL). The results of end-of-treatment (EOT) FDG-PET/CT are more accurate for detection of active disease with residual masses on CT. Complete response defined by EOT FDG-PET/CT (PET-CR) correlates with long-term outcome of patients. Treatment efficacy is determined using EOT PET/CT rather than progression-free survival (PFS) for clinical trials assessing novel drugs. If the correlation of EOT PET/CT with PFS is further proven in large studies and meta-analyses, EOT PET-CR could serve as an expedited novel endpoint replacing PFS.”",

keywords = "Diffuse large B-cell lymphoma, End-of-treatment PET-CT, FDG-PET/CT, Prediction of outcome",

author = "Lale Kostakoglu and Nowakowski, {Grzegorz S}",

year = "2019",

month = jul,

day = "1",

doi = "10.1016/j.cpet.2019.03.001",

language = "English (US)",

volume = "14",

pages = "307--315",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma

AU - Kostakoglu, Lale

AU - Nowakowski, Grzegorz S

PY - 2019/7/1

Y1 - 2019/7/1

N2 - “PET imaging with fluorodeoxyglucose (FDG), integrated with PET/computed tomography (FDG-PET/CT), is an effective management tool of diffuse large B-cell lymphoma (DLBCL). The results of end-of-treatment (EOT) FDG-PET/CT are more accurate for detection of active disease with residual masses on CT. Complete response defined by EOT FDG-PET/CT (PET-CR) correlates with long-term outcome of patients. Treatment efficacy is determined using EOT PET/CT rather than progression-free survival (PFS) for clinical trials assessing novel drugs. If the correlation of EOT PET/CT with PFS is further proven in large studies and meta-analyses, EOT PET-CR could serve as an expedited novel endpoint replacing PFS.”

AB - “PET imaging with fluorodeoxyglucose (FDG), integrated with PET/computed tomography (FDG-PET/CT), is an effective management tool of diffuse large B-cell lymphoma (DLBCL). The results of end-of-treatment (EOT) FDG-PET/CT are more accurate for detection of active disease with residual masses on CT. Complete response defined by EOT FDG-PET/CT (PET-CR) correlates with long-term outcome of patients. Treatment efficacy is determined using EOT PET/CT rather than progression-free survival (PFS) for clinical trials assessing novel drugs. If the correlation of EOT PET/CT with PFS is further proven in large studies and meta-analyses, EOT PET-CR could serve as an expedited novel endpoint replacing PFS.”

KW - Diffuse large B-cell lymphoma

KW - End-of-treatment PET-CT

KW - FDG-PET/CT

KW - Prediction of outcome

UR - http://www.scopus.com/inward/record.url?scp=85065477821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065477821&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2019.03.001

DO - 10.1016/j.cpet.2019.03.001

M3 - Review article

C2 - 31084771

AN - SCOPUS:85065477821

SN - 1556-8598

VL - 14

SP - 307

EP - 315

JO - PET Clinics

JF - PET Clinics

IS - 3

ER -

End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this